Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus capecitabine versus capecitabine alone as postoperative adjuvant therapy for resectable advanced extrahepatic biliary tract malignancies
ChiCTR2600135977Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab and capecitabine in gallbladder cancer, hilar cholangiocarcinoma (HC), distal cholangiocarcinoma (dCCA) and 1 more (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: 1-year recurrence-free survival rate. Started Oct 2024; status: recruiting.
02
Drugs
toripalimabcapecitabine
03
Conditions
gallbladder cancerhilar cholangiocarcinoma (HC)distal cholangiocarcinoma (dCCA)extrahepatic cholangiocarcinoma (eCCA)
Beyond the preview
Go deeper on ChiCTR2600135977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135977.